Benitec Biopharma Inc.: Form 10-K/A for the period ended Jun 30, 2025
Filed with the SEC on Mar 20, 2026 and accepted by EDGAR at Mar 20, 2026, 16:03 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2025-04-01 to 2025-06-30 | $2.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2024-07-01 to 2025-06-30 | $18.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$9.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2024-07-01 to 2025-06-30 | −$41.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$8.8m | us-gaap:NetIncomeLoss |
| Net income | 12 months2024-07-01 to 2025-06-30 | −$37.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2024-07-01 to 2025-06-30 | −$1.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2024-07-01 to 2025-06-30 | −$1.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 41,161,259 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2024-07-01 to 2025-06-30 | 36,209,271 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-07-01 to 2025-06-30 | −$23.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2024-07-01 to 2025-06-30 | $18.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-06-30 | $97.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $98.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $99.6m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $1.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $2.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-30 | $97.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-26-117604. Last ingested by Listed: Nov 14, 2026, 11:28 ET. Listed shows no prices and gives no investment advice.